Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novan Therapeutics raises $50m

This article was originally published in Scrip

Executive Summary

The private biotech company Novan Therapeutics has secured $50m in an oversubscribed private financing. New investor Malin was the main contributor, with Novan's existing private investors also participating. The round closed on 27 March, including an August 2014 initial filing of $10.3m. The Durham, North Carolina-based Noven will use the funds to develop its first-in-class, nitric oxide-based products in a number of "large market indications". Neal Hunter, Novan's Founding Investor and Chairman, stated: "We believe the promise of Novan's pipeline and our advancement toward commercialization enabled us to attract strong participation in this round, leading us to close at twice the original target of $25 million." Novan's lead product ,SB204, is in late-stage development as a new treatment for acne vulgaris that may help curb the overuse of topical and oral antibiotics for this condition. Clinical studies so far suggest it is well-tolerated solution with a rapid onset of action. Novan expects to complete its current Phase IIb clinical study of SB204 this summer and hopes to enter Phase III early 2016. It also plans to start clinical development of SB206, a topical anti-viral for human papillomavirus (HPV) infections. It is due to enter a Phase II clinical trial in the second quarter for the treatment of external genital warts.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC028292

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel